LifeSci Advisors is a Biotech Investor Relations consultancy that provides equity research to clients in medical life-sciences. LifeSci Advisors is a Pharmaceutical Investor Relations consultancy that provides equity research to clients in medical life-sciences. LifeSci Advisors is an Equity Research consultancy that provides equity research to clients in medical life-sciences. LifeSci Advisors is a Corporate Communications consultancy that provides equity research to clients in medical life-sciences. LifeSci Advisors is a Biotechnology consultancy that provides equity research to clients in medical life-sciences. LifeSci Advisors is a Biotech Investor Relations consultancy that provides equity research to clients in medical life sciences. LifeSci Advisors is a Pharmaceutical Investor Relations consultancy that provides equity research to clients in medical life sciences. LifeSci Advisors is an Investor Relations consultancy that provides equity research to clients in Healthcare LifeSci Advisors is an Equity Research consultancy that provides equity research to clients in Pharmaceuticals. LifeSci Advisors is a Corporate Communications consultancy that provides equity research to clients in Medical Devices. LifeSci Advisors is a Healthcare Investor consultancy that provides equity research to clients in Medical Devices. LifeSci Advisors is a Pharmaceutical Investor consultancy that provides equity research to clients in Medical Devices.

Web developed by Bolinger web design

Our Distribution


News LifeSci

Adocia Announced Positive Phase IIa Results for Ul...

Adocia Announced Positive Phase IIa Results for Ultra-Fast Acting BioChaperone Lispro-

LifeSci Advisors

Like Tweet This! Share on LinkedIn

Adocia Announced Positive Phase IIa Results for Ultra-Fast Acting BioChaperone Lispro


On April 9, Adocia (ADOC.PA) announced positive top- line results from a Phase IIa trial for BioChaperone Lispro, the Company’s formulation of ultra-fast acting insulin lispro for the management of type 1 and type 2 diabetes. This product incorporates Adocia’s proprietary BioChaperone technology, which is designed to facilitate the delivery of therapeutic proteins and antibodies. The positive results add to a growing body of evidence supporting the potential of BioChaperone insulin products to treat diabetes,

Stemline Received IND Approval to Advance SL-701 i...

Stemline Received IND Approval to Advance SL-701 into Phase 2 Trial-

LifeSci Advisors

Like Tweet This! Share on LinkedIn

Stemline Received IND Approval to Advance SL-701 into Phase 2 Trial

~SL-501 Data Presented at AACR~

Stemline Therapeutics (Nasdaq: STML) announced on April 8th that the FDA has accepted an IND for SL-701, a synthetic multi-peptide vaccine targeting glioma brain tumors. SL-701 will be advanced into a Phase 2 trial in adults with glioblastoma multiforme (GBM) in first recurrence. A 2014 IND filing is also planned for the Company’s other clinical-stage drug, SL-401. In addition, preclinical data were presented at the 2014 American Association for Cancer

DelMar Pharmaceuticals Presented Updated Progress ...

DelMar Pharmaceuticals Presented Updated Progress for VAL-083 at AACR-

LifeSci Advisors

Like Tweet This! Share on LinkedIn

DelMar Pharmaceuticals Presented Updated Progress for VAL-083 at AACR
DelMar Pharmaceuticals (OTCQB: DMPI) presented an update of the ongoing Phase I/II trial with VAL-083 as a treatment for glioblastoma multiforme (GBM) at the 2014 American Association for Cancer Research Meeting in San Diego on April 9. The Company also presented preclinical data with VAL-083 in xenograft models of non-small cell lung cancer.
Jerry Isaacson, Ph.D.

Adam Evertts, Ph.D.

Andrew I. McDonald, Ph.D.

VAL-083 Glioblastoma Clinical Trials Continues Enrollment under Accelerated Schedule. DelMar announced in November 2013

TiGenix Announces Exclusive License of ChondroCele...

TiGenix Announces Exclusive License of ChondroCelect to Sobi-

LifeSci Advisors

Like Tweet This! Share on LinkedIn

TiGenix Announces Exclusive License of ChondroCelect to Sobi

On April 3, TiGenix (TIG.BR) announced the licensing of exclusive marketing and distribution rights for ChondroCelect to Swedish Orphan Biovitrum AB, also known as Sobi (SOBI.ST). Sobi will assume all commercial and distribution responsibilities, and the majority of the costs for the product, and TiGenix will receive a royalty of 22% of net sales in the first year and 20% thereafter. This deal greatly reduces risk for TiGenix and allows the Company to focus resources on their promising

Phase I Cohort Expansion with Lirilumab and Nivolu...

Phase I Cohort Expansion with Lirilumab and Nivolumab Begins-

LifeSci Advisors

Like Tweet This! Share on LinkedIn

Phase I Cohort Expansion with Lirilumab and Nivolumab Begins

~Upcoming R&D Day on April 10th~

Innate Pharma announced that partner Bristol-Myers Squibb (BMY) began cohort expansion for a Phase I clinical trial with lirilumab and nivolumab in selected solid tumors. The Company also received a second positive Data and Safety Monitoring Board (DSMB) assessment of their Phase II trial with lirilumab in elderly acute myeloid leukemia (AML) patients. More than 100 patients have now been enrolled. Innate will webcast a research and development day on April

Adocia Releases Positive Data from Phase I Trial w...

Adocia Releases Positive Data from Phase I Trial with BioChaperone Combo-

LifeSci Advisors

Like Tweet This! Share on LinkedIn

Adocia Releases Positive Data from Phase I Trial with BioChaperone Combo

~Phase IIa Trial Expected in 2014~


On March 20th, Adocia (ADOC.PA) released additional positive clinical trial results with BioChaperone Combo, the first mix of slow acting (basal) insulin glargine and a fast-acting (prandial) insulin analog. The Company reported that BioChaperone Combo had a significantly faster onset and duration of action compared to Humalog Mix25. Adocia intends to launch a Phase IIa trial with Combo in the third quarter of 2014, with data expected by

LifeSci Advisors Initiates Coverage of Cancer Gene...

LifeSci Advisors Initiates Coverage of Cancer Genetics-

LifeSci Advisors

Like Tweet This! Share on LinkedIn

LifeSci Advisors Initiates Coverage of Cancer Genetics, Inc.Strong Portfolio of Unique Genomic Diagnostic Tests for Personalized Medicine in Oncology

Consistent Revenue and Gross Profit Growth; $6.6 Million in 2013 Revenue

LifeSci Investment AbstractCancer Genetics, Inc. (NASDAQ: CGIX) is a leader in personalized oncology diagnostics, providing proprietary genomic products, clinical cancer testing, and clinical trial services to help with diagnosis and improve the success rate of treatment. The Company has five approved products for the diagnosis of hematological, urogenital, and gynecological malignancies, and reported strong

Cynapsus Announced Positive Interim Phase I Data f...

Cynapsus Announced Positive Interim Phase I Data for APL-130277-

LifeSci Advisors

Like Tweet This! Share on LinkedIn

Cynapsus Announced Positive Interim Phase I Data for APL-130277 
On March 28th, Cynapsus Therapeutics (Other OTCQX: CYNAF) announced preliminary results from an ongoing pharmacokinetic study of APL-130277, a sublingual delivery formulation of apomorphine for the acute rescue of motor fluctuations in Parkinson’s disease patients. Results from the trial indicate that the 25 mg of apomorphine on the sublingual strip leads to an increase in blood concentration of the drug relative to the 15 mg dose. Final results from the trial are expected in April 2014.

BioLife Solutions Raises $15.4 Million and Elimina...

BioLife Solutions Raises $15.4 Million and Eliminates All Debt-

 

LifeSci Advisors

Like Tweet This! Share on LinkedIn

BioLife Solutions Raises $15.4 Million and Eliminates All Debt 
On March 26th, BioLife Solutions (NASDAQ CM: BLFS) completed a series of steps that culminated in a public offering that raised $15.4 million and up-listing of the Company’s shares to trade on the NASDAQ Capital Market, substantially improving the Company’s capital structure. In conjunction with the financing, BioLife converted the entirety of its $14.3 million in debt, replacing the debt with equity and putting the Company on the path to being cash-flow positive.
Jerry Isaacson

NeoStem Announces 2013 Financial Results...

NeoStem Announces 2013 Financial Results-

 
LifeSci Advisors

Like Tweet This! Share on LinkedIn

NeoStem Announces 2013 Financial Results~Phase II PreSERVE Trial Received Fourth Positive DSMB Review~
On March 13th, NeoStem, Inc. (NBS) announced full year financial results for 2013, reporting a 14% increase in clinical service revenues from Progenitor Cell Therapy (PCT) due to adding 50% more active clients. Enrollment in the Phase II PreSERVE trial for acute myocardial infraction is complete. The trial received a fourth positive Data Safety and Monitoring Board (DSMB) review, and data are expected in the second half of 2014.
Jerry Isaacson,

LifeSci Advisors Initiates Coverage of Oramed Phar...

LifeSci Advisors Initiates Coverage of Oramed Pharmaceuticals-

 
LifeSci Advisors

Like Tweet This! Share on LinkedIn

LifeSci Advisors Initiates Coverage of Oramed Pharmaceuticals

Oramed’s Oral Insulin Development Program is in
Phase II for the Treatment of Diabetes

LifeSci Investment Abstract

Oramed Pharmaceuticals (NASDAQ: ORMP) is a clinical-stage pharmaceutical company specializing in the oral delivery of proteins for large disease indications. Lead candidate ORMD-0801 is an oral insulin candidate in Phase II development to control fasting blood glucose levels in diabetes. Oramed is also developing an oral glucagon-like peptide 1 (GLP-1) receptor agonist and an insulin/GLP-1 combination product.


Jerry Isaacson, Ph.D.
(646)

LifeSci Advisors Initiates Coverage of Erytech...

LifeSci Advisors Initiates Coverage of Erytech-

 
LifeSci Advisors

Like Tweet This! Share on LinkedIn

LifeSci Advisors Initiates Coverage of Erytech

Lead Candidate GRASPA/ERY-ASP is in a European Phase III Trial
and US Phase I/II Trial

Erytech Platform Technology Employs Red Blood Cells in the Fight Against Cancer

LifeSci Investment Abstract

Erytech Pharma (NYSE Euronext: ERYP.PA) is a biopharmaceutical company developing unique, red blood cell-based treatments for cancer that went public in April 2013. The Company’s lead candidate is GRASPA/ERY-ASP, a red blood cell encapsulated L-asparaginase therapy in development for patients with acute leukemia. Data from a European Phase III trial

La Jolla Pharmaceutical Announces Positive Data fr...

La Jolla Pharmaceutical Announces Positive Data from Phase 2 Trial of GCS-100 in CKD-

 
LifeSci Advisors

Like Tweet This! Share on LinkedIn

La Jolla Pharmaceutical Announces Positive Data from
Phase 2 Trial of GCS-100 in CKD

Primary Endpoint of Improved Kidney Function Reached

On March 10th, La Jolla Pharmaceutical (LJPC) announced positive results from their randomized, placebo-controlled Phase 2 clinical trial testing GCS-100 in chronic kidney disease (CKD). The lower dose of GCS-100 met the primary endpoint by improving patients’ kidney function from baseline as measured by estimated glomerular filtration rate (eGFR) compared to placebo.
Jerry Isaacson, Ph.D.
(646) 597-6991
jerry@lifesciadvisors.com

Adam Evertts, Ph.D.
adam@lifesciadvisors.com
Andrew

BioAmber Announces 2013 Annual Financial Results...

BioAmber Announces 2013 Annual Financial Results-

 

 
LifeSci Advisors

Like Tweet This! Share on LinkedIn

BioAmber Announces 2013 Annual Financial Results

On March 13, BioAmber (NYSE: BIOA) released financial results for 2013. The Company reported that despite poor weather conditions, significant progress is being made on the Sarnia plant and costs are on budget. BioAmber added 18 new customers in 2013 and validated new uses for bio-succinic acid. In January 2014, the Company signed a 15-year take-or-pay agreement with Vinmar for the purchase of 100% of bio-BDO production from a production facility that is expected to be commissioned in 2017.

Ohr Launches Joint Venture with Cold Spring Harbor...

Ohr Launches Joint Venture with Cold Spring Harbor for Trodusquemine-

Ohr Pharmaceutical Update
Ohr Launches Joint Venture with Cold Spring Harbor Labs for Trodusquemine
LifeSci Advisors

Like Tweet This! Share on LinkedIn

Ohr Launches Joint Venture with Cold Spring Harbor for Trodusquemine

~Positive Case Report with Squalamine Presented at Scientific Conference~


On March 3rd, 2014, Ohr Pharmaceutical (NASDAQ: OHRP) announced a joint venture with Cold Spring Harbor Laboratory (CSHL) to develop trodusquemine and related analogs. The deal allows Ohr to focus on the development of its ophthalmology portfolio while preserving the potential to create shareholder value with trodusquemine. Also, a positive case report was

Contact Us   |   About Us   |   Privacy Policy   |   Disclaimer  |   Careers

©2014 LifeSci Advisors, LLC. All Rights Reserved.

email


Web developed by Bolinger web design